*Applications will be reviewed on a rolling-basis.
An opportunity is available at the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), in the Office of Surveillance and Epidemiology / Office of Medication Error Prevention and Risk Management located in Silver Spring, Maryland.
The Network for Excellence in Health Innovation estimates that outpatient and inpatient preventable medication errors have an annual cost of nearly $21 billion. This project aims to enhance FDA’s pharmacovigilance program to identify and prevent errors associated with CDER-regulated products. Under the guidance of a mentor, the participant will research regulatory approaches to address medication error-related issues associated with drug products. Through this research, the participant will gain experience understanding the causes of medication errors, and learn to identify how medication errors play a role in drug nomenclature, packaging, labels and labeling, and the role of human factors in addressing these errors.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity in your email.